Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

Vivo Capital

Latest statistics and disclosures from Vivo Capital's latest quarterly 13F-HR filing:

Top 5 stock holdings are TERN, CDTX, PRAX, COGT, TRVI, and represent 43.52% of Vivo Capital's stock portfolio.
Added to shares of these 10 stocks: PRAX (+$38M), DBVT (+$27M), ANRO (+$18M), NERV (+$17M), DSGN (+$15M), MLTX (+$13M), TNGX (+$12M), PALI (+$5.4M), KTTA, CAMP.
Started 7 new stock positions in MLTX, ENGNW, DSGN, NERV, KTTA, ANRO, PALI.
Reduced shares in these 10 stocks: VRNA (-$149M), CDTX (-$78M), SLNO (-$64M), TERN (-$63M), TRML (-$28M), OLMA (-$21M), AKRO (-$21M), RZLT (-$20M), COGT (-$14M), ZBIO (-$12M).
Sold out of its positions in AKRO, Astria Therapeutics, DCTH, ETNB, RZLT, TRML, VRNA.
Vivo Capital was a net seller of stock by $-360M.
Vivo Capital has $1.5B in assets under management (AUM), dropping by 24.49%.
Central Index Key (CIK): 0001674712

Tip: Access up to 7 years of quarterly data

Positions held by Vivo Capital consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Vivo Capital

Vivo Capital holds 47 positions in its portfolio as reported in the December 2025 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
Terns Pharmaceuticals Common (TERN)	14.0	$216M	-22%	5.3M	40.40	View chart
Cidara Therapeutics Common (CDTX)	13.7	$211M	-27%	957k	220.89	View chart
Praxis Precision Medicines Common (PRAX)	6.3	$97M	+65%	329k	294.74	View chart
Cogent Biosciences Common (COGT)	5.5	$85M	-13%	2.4M	35.52	View chart
Trevi Therapeutics Common (TRVI)	4.1	$64M		5.1M	12.52	View chart
Avadel Pharmaceuticals Adr (AVDL)	3.7	$58M		2.7M	21.55	View chart
Compass Therapeutics Common (CMPX)	3.3	$51M		9.5M	5.37	View chart
Dyne Therapeutics Common (DYN)	3.3	$51M		2.6M	19.56	View chart
Abivax SA - Sponsored Ads (ABVX)	3.1	$49M		359k	134.85	View chart
DBV Technologies SA Sponsored Ads (DBVT)	3.1	$47M	+133%	2.5M	19.17	View chart
SAB Biotherapeutics Common (SABS)	2.8	$43M		11M	3.74	View chart
Soleno Therapeutics Common (SLNO)	2.7	$41M	-60%	895k	46.30	View chart
Bright Minds Biosciences Common (DRUG)	2.5	$39M		502k	78.04	View chart
Sinovac Biotech SHS	2.5	$38M		5.9M	6.47	View chart
Geron Corp Common (GERN)	2.3	$36M		27M	1.32	View chart
Erasca Common (ERAS)	2.2	$35M		9.3M	3.72	View chart
Zenas Biopharma Common (ZBIO)	2.0	$31M	-27%	854k	36.31	View chart
Viridian Therapeutics Common (VRDN)	2.0	$31M		983k	31.12	View chart
Aclaris Therapeutics Common (ACRS)	1.7	$27M		8.9M	3.01	View chart
CAMP4 Therapeutics Common (CAMP)	1.7	$26M	+8%	4.2M	6.13	View chart
Tango Therapeutics Common (TNGX)	1.2	$19M	+177%	2.2M	8.86	View chart
Alto Neuroscience Common (ANRO)	1.2	$18M	NEW	1.0M	17.80	View chart
LB Pharmaceuticals Common (LBRX)	1.2	$18M		800k	22.26	View chart
Minerva Neurosciences Common (NERV)	1.1	$17M	NEW	4.3M	4.02	View chart
Oric Pharmaceuticals Common (ORIC)	1.1	$17M	-32%	2.1M	8.18	View chart
Corvus Pharmaceuticals Holdings Common (CRVS)	1.1	$17M		2.2M	7.70	View chart
Olema Pharmaceuticals Common (OLMA)	1.1	$17M	-55%	672k	25.00	View chart
Pepgen Common (PEPG)	1.0	$15M		2.3M	6.51	View chart
Design Therapeutics Common (DSGN)	1.0	$15M	NEW	1.6M	9.38	View chart
Dianthus Therapeutics Common (DNTH)	0.9	$15M		354k	41.21	View chart
Moonlake Immunotherapeutics Common (MLTX)	0.9	$13M	NEW	1.0M	13.18	View chart
Cytomx Therapeutics Common (CTMX)	0.8	$12M		2.9M	4.26	View chart
Unicycive Therapeutics Common (UNCY)	0.7	$10M		1.8M	5.77	View chart
Eupraxia Pharmaceuticals Common (EPRX)	0.7	$10M		1.4M	7.55	View chart
Abeona Therapeutics Common (ABEO)	0.6	$9.7M		1.8M	5.27	View chart
Verastem Common (VSTM)	0.6	$8.5M	-58%	1.1M	7.72	View chart
Silence Therapeutics Ads (SLN)	0.4	$6.7M		1.1M	6.08	View chart
Monopar Therapeutics Common (MNPR)	0.4	$5.9M		91k	65.30	View chart
Surrozen Common (SRZN)	0.4	$5.9M		260k	22.60	View chart
Palisade Bio Common (PALI)	0.3	$5.4M	NEW	2.3M	2.35	View chart
Sera Prognostics Common (SERA)	0.3	$4.9M		1.7M	2.95	View chart
Instil Bio Common (TIL)	0.2	$3.2M		293k	11.00	View chart
Pasithea Therapeutics Corp Common (KTTA)	0.2	$2.7M	NEW	2.1M	1.29	View chart
Tenax Therapeutics Common (TENX)	0.2	$2.5M		208k	12.19	View chart
EnGene Holdings Warrants (ENGNW)	0.1	$844k	NEW	285k	2.96	View chart
Bolt Therapeutics Common (BOLT)	0.0	$396k	-58%	72k	5.47	View chart
Precision Biosciences Common (DTIL)	0.0	$19k		4.7k	4.16	View chart

Past Filings by Vivo Capital

SEC 13F filings are viewable for Vivo Capital going back to 2016

Vivo Capital 2025 Q4 filed Feb. 13, 2026
Vivo Capital 2025 Q3 filed Nov. 14, 2025
Vivo Capital 2025 Q2 filed Aug. 14, 2025
Vivo Capital 2025 Q1 filed May 12, 2025
Vivo Capital 2024 Q4 filed Feb. 13, 2025
Vivo Capital 2024 Q3 filed Nov. 13, 2024
Vivo Capital 2024 Q2 filed Aug. 14, 2024
Vivo Capital 2024 Q1 filed April 22, 2024
Vivo Capital 2023 Q4 filed Feb. 7, 2024
Vivo Capital 2023 Q3 filed Nov. 8, 2023
Vivo Capital 2023 Q2 filed Aug. 14, 2023
Vivo Capital 2023 Q1 filed May 15, 2023
Vivo Capital 2022 Q4 filed Feb. 13, 2023
Vivo Capital 2022 Q3 filed Nov. 14, 2022
Vivo Capital 2022 Q2 filed Aug. 15, 2022
Vivo Capital 2022 Q1 filed May 13, 2022

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z